253 related articles for article (PubMed ID: 30353413)
1. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
Li B; Mascarenhas JO; Rampal RK
Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
[TBL] [Abstract][Full Text] [Related]
2. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
Rampal R; Mascarenhas J
Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
[TBL] [Abstract][Full Text] [Related]
4. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
5. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
7. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
8. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.
Ding Y; Harada Y; Imagawa J; Kimura A; Harada H
Blood; 2009 Dec; 114(25):5201-5. PubMed ID: 19850737
[TBL] [Abstract][Full Text] [Related]
9. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
[TBL] [Abstract][Full Text] [Related]
10. Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
Kim T; Ahn JS; Son MH; Novitzky-Basso I; Yi SY; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Moon JH; Sohn SK; Kim HJ; Zhang Z; Kim DDH
Leuk Res; 2022 Jul; 118():106858. PubMed ID: 35609360
[TBL] [Abstract][Full Text] [Related]
11. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
12. Leukemia secondary to myeloproliferative neoplasms.
Dunbar AJ; Rampal RK; Levine R
Blood; 2020 Jul; 136(1):61-70. PubMed ID: 32430500
[TBL] [Abstract][Full Text] [Related]
13. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
Zhang SJ; Abdel-Wahab O
Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis- and Prognosis-Related Gene Alterations in
Morishita S; Komatsu N
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
[No Abstract] [Full Text] [Related]
15. Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach.
Homaei Hadad E; Pezeshki SMS; Shahrabi S; Saki Malehi A; Saki N
Expert Rev Hematol; 2020 Nov; 13(11):1289-1301. PubMed ID: 32886563
[TBL] [Abstract][Full Text] [Related]
16. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
Abruzzese E; Niscola P
Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
[No Abstract] [Full Text] [Related]
17. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
Li Y; Zhang XY; Han J; Wang L
Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397
[TBL] [Abstract][Full Text] [Related]
18. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
19. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
20. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]